2001 to 2020 Saw Shift in Rx for Disease-Modifying Therapy for Multiple Sclerosis
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, July 27, 2023 -- Oral disease-modifying therapies (DMTs) predominated new initiations for treatment of multiple sclerosis (MS) in 2020, according to a study published online July 10 in JAMA Neurology.
Mackenzie Henderson, Pharm.D., from Rutgers University in New Brunswick, New Jersey, and colleagues examined real-world prescribing patterns of DMTs for MS. The analysis captured 153,846 DMT initiation episodes for adults and 583 DMT initiation episodes among children, of whom 113,583 patients (113,095 adults and 488 children) had initiation of at least one DMT, identified from MarketScan U.S. commercial claims data (2001 through 2020).
The researchers found that among adults, use of platform injectables showed an absolute decline of 73.8 percent during the study period, driven by a 61.2 percent decline in interferon β initiations. Initiation of oral DMTs increased as a share of all DMT initiations following their 2010 introduction (from 1.1 percent in 2010 to 62.3 percent in 2020). Over time, infusion therapy initiations remained relatively low, accounting for 3.2 percent of all initiations since their introduction in 2004, although there was a modest annual increase after ocrelizumab was introduced in 2017, reaching 8.2 percent of all initiations in 2020. Patterns were similar in children, except for oral therapy preference. In adults, dimethyl fumarate was the most commonly initiated DMT in 2019 to 2020 (23.3 to 27.2 percent of all initiations). In children, fingolimod was the most commonly initiated (34.8 to 68.8 percent) in 2019 to 2020.
"The increasing use of oral therapies may have been due to multiple factors, including convenience, insurance restrictions, or direct-to-consumer advertising," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Slight Body Mass Gains in Middle Age May Cut Later Fracture Risk
FRIDAY, May 17, 2024 -- People whose body mass index (BMI) slightly increases from normal weight to low-level overweight during 30 years of middle adulthood have a lower risk for...
High Level of Approval Observed for Polygenic Embryo Screening
FRIDAY, May 17, 2024 -- There is a high level of approval for use of polygenic embryo screening, according to a study published online May 14 in JAMA Network Open. Rémy A...
AI Chatbots Can Generate Quality, Empathetic, Readable Responses
FRIDAY, May 17, 2024 -- For patient questions about cancer, artificial intelligence (AI) chatbots can generate quality, empathetic, and readable responses, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.